Orlistat: Current issues for patients with type 2 diabetes
- 84 Downloads
Orlistat, a pancreatic lipase inhibitor, was approved by the US Food and Drug Administration (FDA) in the spring of 1999 as an adjunct to lifestyle intervention for weight loss. This paper seeks to examine current issues regarding orlistat use in patients with type 2 diabetes. There are a number of trials that demonstrate the bene fits of orlistat over placebo for reducing body weight and improving other health parameters. Of some interest are the preliminary explorations of interaction on cytokine levels, where a possible cardiovascular benefit is plausible. Implications of the FDA approval of over-the-counter use and the pharmaceutical development of another lipase inhibitor are also examined.
KeywordsMetformin Lifestyle Intervention Orlistat Sibutramine Lipase Inhibitor
Unable to display preview. Download preview PDF.
References and Recommended Reading
- 1.WIN Weight-control Information Network: Statistics related to overweight and obesity. http://win.niddk.nih. gov/statistics/index.htm. Accessed March 5, 2006.Google Scholar
- 2.National Institutes of Health National Heart, Lung, and Blood Institute in cooperation with The National Institute of Diabetes and Digestive and Kidney Diseases: Clinical Guidelines on the Identification, Evaluation and Treatment of Overweight and Obesity in Adults. The evidence report. NIH Publication #98-4083. Bethesda, MD: National Institutes of Health; 1998.Google Scholar
- 3.Zhaoping L, Maglione M, Tu W, et al.: Meta-analysis: pharmacologic treatment of obesity. Ann Intern Med 2005, 142:532–546.Google Scholar
- 7.Hutton B, Ferguson D: Changes in body weight and serum lipid profile in obese patients treated with orlistat in addition to a hypocaloric diet: a systematic review of randomized clinical trials. Am J Clin Nutr 2004, 80:1461–1468. An excellent review of the trials that establish that orlistat with lifestyle intervention is more effective than lifestyle intervention alone for weight loss.PubMedGoogle Scholar
- 19.Torgerson J, Hauptman J, Boldrin M, et al.: XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004, 27:155–161. This excellent report details the use of orlistat in a prospective randomized diabetes prevention clinical trial.PubMedCrossRefGoogle Scholar